Note 5 - Certain Balance Sheet Accounts (Tables)
|
6 Months Ended |
Jun. 30, 2026 |
|---|
| Notes Tables |
|
| Schedule Of Contract Royalty Asset [Table Text Block] |
| |
|
June 30,
|
|
|
December 31,
|
|
| |
|
2026
|
|
|
2025
|
|
| |
|
(In thousands)
|
|
|
Short-term contract royalty asset
|
|
$ |
25,603 |
|
|
$ |
25,351 |
|
|
Long-term contract royalty asset
|
|
|
90,875 |
|
|
|
96,435 |
|
|
Total OMIDRIA contract royalty asset
|
|
$ |
116,478 |
|
|
$ |
121,786 |
|
|
| Schedule of Royalty Obligation, Financial Position [Table Text Block] |
| |
|
June 30,
|
|
|
December 31,
|
|
| |
|
2026
|
|
|
2025
|
|
| |
|
(In thousands)
|
|
|
Short-term OMIDRIA royalty obligation
|
|
$ |
21,511 |
|
|
$ |
20,547 |
|
|
Long-term OMIDRIA royalty obligation
|
|
|
136,370 |
|
|
|
147,319 |
|
|
Total OMIDRIA royalty obligation
|
|
$ |
157,881 |
|
|
$ |
167,866 |
|
|
| Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] |
| |
|
June 30,
|
|
|
December 31,
|
|
| |
|
2026
|
|
|
2025
|
|
| |
|
(In thousands)
|
|
|
Trade receivables, net
|
|
$ |
11,711 |
|
|
$ |
— |
|
|
OMIDRIA royalty receivables
|
|
|
6,109 |
|
|
|
6,443 |
|
|
Novo Nordisk receivable
|
|
|
3,370 |
|
|
|
3,724 |
|
|
Other receivables
|
|
|
111 |
|
|
|
750 |
|
|
Total receivables
|
|
$ |
21,301 |
|
|
$ |
10,917 |
|
|
| Property, Plant, and Equipment [Table Text Block] |
| |
|
June 30,
|
|
|
December 31,
|
|
| |
|
2026
|
|
|
2025
|
|
| |
|
(In thousands)
|
|
|
Equipment under finance lease obligations
|
|
$ |
8,324 |
|
|
$ |
8,323 |
|
|
Laboratory equipment
|
|
|
3,788 |
|
|
|
3,744 |
|
|
Computer equipment
|
|
|
1,113 |
|
|
|
1,113 |
|
|
Office equipment and furniture
|
|
|
624 |
|
|
|
624 |
|
|
Total cost
|
|
|
13,849 |
|
|
|
13,804 |
|
|
Less accumulated depreciation and amortization
|
|
|
(12,469 |
) |
|
|
(12,036 |
) |
|
Total property and equipment, net
|
|
$ |
1,380 |
|
|
$ |
1,768 |
|
|
| Schedule of Accrued Liabilities [Table Text Block] |
| |
|
June 30,
|
|
|
December 31,
|
|
| |
|
2026
|
|
|
2025
|
|
| |
|
(In thousands)
|
|
|
Employee compensation
|
|
$ |
11,830 |
|
|
$ |
10,348 |
|
|
Deferred income
|
|
|
5,004 |
|
|
|
2,473 |
|
|
Clinical trials
|
|
|
4,610 |
|
|
|
6,248 |
|
|
Contract research and development
|
|
|
3,928 |
|
|
|
5,773 |
|
|
Consulting and professional fees
|
|
|
1,802 |
|
|
|
2,406 |
|
|
Sales, fees and discounts
|
|
|
831 |
|
|
|
— |
|
|
Income taxes payable
|
|
|
656 |
|
|
|
1,146 |
|
|
Interest payable
|
|
|
280 |
|
|
|
616 |
|
|
Other accrued expenses
|
|
|
328 |
|
|
|
378 |
|
|
Total accrued expenses
|
|
$ |
29,269 |
|
|
$ |
29,388 |
|
|